IR@PKUHSC  > 北京大学第三临床医学院  > 心血管内科
学科主题临床医学
Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease
Wang, Guang1; Zhang, Zhe2; Yu, Jie1; Zhang, Fuchun1; He, Liyun1; Wei, Jinru1; Mao, Jieming1; Wang, Xian1,3,4
刊名PPAR RESEARCH
2008
DOI10.1155/2008/548178
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental
研究领域[WOS]Research & Experimental Medicine
英文摘要

Background. We investigated the level of soluble adhesion molecules in diabetic patients and the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist rosiglitazone on plasma levels of adhesion molecules and an inflammation marker in type 2 diabetic patients with coronary artery disease (CAD) after percutaneous coronary intervention (PCI). Methods. A total of 116 diabetic patients with CAD who had undergone PCI were randomized to receive rosiglitazone (4mg/d) or not for 6 months. Plasma levels of soluble intercellular adhesion molecules (sICAM-1) and P-selectin (sP-selectin) were measured on ELISA. Results. After 6-month rosiglitazone treatment, plasma levels of sICAM-1 were lower than baseline and control group levels (370.4 (332.4-421.9) pg/mL versus 423.5 (327.4-500.3) pg/mL and 404.6 (345.2-483.4) pg/mL, P < .001). In addition, plasma levels of C-reactive protein were significantly reduced from baseline levels. However, plasma level of sP-selectin was not significantly lowered with rosiglitazone treatment than with control treatment after 6-month follow-up. Conclusions. Rosiglitazone reduces chronic inflammatory responses and improves levels of markers of endothelial dysfunction in patients with diabetes and CAD. PPAR-gamma agonist may have a beneficial effect on the vascular endothelium through its anti-inflammatory mechanism and may be useful as therapy in patients undergoing PCI. Copyright (C) 2008 GuangWang et al.

语种英语
WOS记录号WOS:000207691800001
项目编号2006CB503802 ; 30330250 ; 30770873
资助机构Major National Basic Research Program of the P. R. China ; Chinese National Natural Science Foundation
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52193
专题北京大学第三临床医学院_心血管内科
北京大学基础医学院
作者单位1.Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100191, Peoples R China
2.Peking Univ, Hosp 3, Dept Cardiovasc Surg, Beijing 100191, Peoples R China
3.Peking Univ, Dept Physiol & Pathophysiol, Hlth Sci Ctr, Beijing 100083, Peoples R China
4.Peking Univ, Key Lab Mol Cardiovasc Sci, Hlth Sci Ctr, Minist Educ, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Wang, Guang,Zhang, Zhe,Yu, Jie,et al. Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease[J]. PPAR RESEARCH,2008.
APA Wang, Guang.,Zhang, Zhe.,Yu, Jie.,Zhang, Fuchun.,He, Liyun.,...&Wang, Xian.(2008).Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease.PPAR RESEARCH.
MLA Wang, Guang,et al."Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease".PPAR RESEARCH (2008).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Guang]的文章
[Zhang, Zhe]的文章
[Yu, Jie]的文章
百度学术
百度学术中相似的文章
[Wang, Guang]的文章
[Zhang, Zhe]的文章
[Yu, Jie]的文章
必应学术
必应学术中相似的文章
[Wang, Guang]的文章
[Zhang, Zhe]的文章
[Yu, Jie]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。